



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number: 0 449 621 A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 91302717.3

(51) Int. Cl.⁵: C12N 15/53, C12N 9/02,
C12Q 1/66, C12P 21/02

(22) Date of filing: 27.03.91

(30) Priority: 27.03.90 JP 75696/90
30.10.90 JP 294258/90

(43) Date of publication of application:
02.10.91 Bulletin 91/40

(84) Designated Contracting States:
CH DE FR GB LI NL

(71) Applicant: KIKKOMAN CORPORATION
339 Noda
Noda-shi, Chiba-ken (JP)

(72) Inventor: Kajiyama, Naoki
c/o Kikkoman Corporation, 399 Noda
Noda-shi, Chiba-ken (JP)
Inventor: The other inventor has agreed to
waive his entitlement to designation.

(74) Representative: Myerscough, Philip Boyd et al
J.A. Kemp & Co. 14 South Square, Gray's Inn
London WC1R 5LX (GB)

(54) Mutant luciferase of a firefly, mutant luciferase genes, novel recombinant DNAs containing the genes and a method of producing mutant luciferase.

(57) The present invention provides industrially useful mutant luciferase. The luciferase of the invention is produced by culturing a microorganism belonging to the genus *Escherichia* which harbors a recombinant DNA containing the mutant luciferase gene of a firefly. Mutant luciferase can produce light of wavelengths which cannot be produced by wild type luciferase and may be used to measure accurately the amount of ATP in a solution coloured red (e.g., blood), orange, or green in which wild-type luciferase has not provided reliable results.

EP 0 449 621 A1

Field of the Invention:

The present invention relates to mutant luciferase of a firefly, mutant luciferase genes thereof, recombinant DNAs containing the genes and a method of production for the mutant luciferase.

5

Prior Art:

10

Firefly luciferase has been isolated from various fireflies such as Luciola cruciata Luciola lateralis, Photinus pyralis and the like. Luciferase catalyzes luciferin to produce the olive green color (wave length: around 560 nm) of light. There has been no report on firefly luciferase which produces colors of light other than olive green.

Problems to be solved by the Invention

15

When the amount of ATP in a colored solution (e.g., blood) is to be determined by using wild type firefly luciferase, the sensitivity of the measurement is extremely impaired by the color of solution.

20

We have investigated a firefly luciferase which produces light of additional colors. We have successfully prepared a mutant capable of producing red, orange and green colors of light by isolating a wild type luciferase gene, inserting the gene into a vector, treating the construct with mutagens, transforming the genus Escherichia with the mutant, culturing the transformant in a medium, and recovering mutant luciferase producing a green color of light.

25

The present invention comprises the following:

30

(1) A method of producing a mutant luciferase gene by treating a wild type luciferase gene of a firefly with a mutagen.

35

(2) A method of (1) wherein said mutant luciferase gene encodes mutant luciferase catalyzing luciferin to produce red, orange, or green color of light, different from the one produced by native luciferase.

40

(3) A mutant luciferase gene encoding the amino acid sequence of luciferase in which valine is replaced by isoleucine at the amino acid number 233, valine by isoleucine at 239, serine by asparagine at 286, glycine by serine at 326, histidine by tyrosine at 433 or proline by serine at 452.

45

(4) A recombinant DNA comprising the mutant luciferase genes of (3).

50

(5) A method of producing mutant luciferase of a firefly which comprises culturing in a medium a microorganism belonging to the genus Escherichia transformed with a recombinant DNA containing a mutant gene encoding the amino acid sequence of luciferase in which valine is replaced by isoleucine at the amino acid number 233, valine by isoleucine at 239, serine by asparagine at 286, glycine by serine at 326, histidine by tyrosine at 433, proline by serine at 452, and recovering mutant luciferase from the culture.

55

(6) Mutant luciferase having the amino acid sequence in which valine is replaced by isoleucine at the amino acid number 233, valine by isoleucine at 239, serine by asparagine at 286, glycine by serine at 326, histidine by tyrosine at 433, proline by serine at 452 in the sequence of native luciferase.

The invention is further illustrated in detail as follows:

60

Any luciferase gene of a firefly may be used, for example Luciola cruciata, Luciola lateralis, Photinus pyralis and the like. A wild type luciferase gene of a firefly is mutagenized to produce mutant luciferase genes. In mutagenesis of a wild type luciferase gene, a wild type luciferase gene alone may be mutagenized or a wild type luciferase gene is inserted in a vector (e.g., plasmid, bacteriophage) and then the construct is mutagenized.

65

A wild type luciferase gene of Luciola cruciata and its recombinant DNA can be obtained by the method described in the Japanese Patent Appln. LOP Publication No. 51086/1989. A wild type luciferase gene of Luciola lateralis and its recombinant DNA can be obtained by the method described in the Japanese Patent Appln. LOP Publication No. 322029/1988.

70

A wild type luciferase gene of a firefly or a recombinant DNA containing the gene is treated with mutagens such as hydroxylamine, N-methyl-N-nitro-N-nitrosoguanidine, nitrous acid, sulfuric acid, hydrazine, formic acid or 5-bromouracil. Though any concentration of a mutagen may be used, 0.5-12 M is preferable. The treatment may be carried out at 20-80°C for more than 10 minutes, preferably 10-180 minutes. Alternatively, a wild type luciferase gene of a firefly or a recombinant DNA containing the gene may be exposed to UV light for 10-60 minutes. Chemically or enzymatically synthesized oligonucleotides may be also utilized.

75

The mutant genes thus obtained are inserted into a vector such as plasmid or bacteriophage (Japanese Patent Appln. LOP Publication No. 51086/1989, Japanese Patent Appln. No. 322029/1988) according to the method known in the art. The constructs are used to transform a microorganism belonging to the genus Escherichia such as E. coli JMI01 (ATCC 33876), DHI (ATCC 33849) and HBI01 (ATCC 33694) according to the method described by Hanahan, 1985, DNA Cloning, 1: 109-135. Alternatively, the constructs are used for transduction according to the method (Molecular Cloning, 1982, Cold Spring Harbor Laboratory).

The transformants and transductants are screened for the production of mutant luciferase. A transformant capable of producing mutant luciferase is selected.

Purified recombinant DNA is obtained from the transformant according to the method described by Guerry, P., 1973, J. Bacteriology, 116: 1064-1066 and Clewell, D.B., 1972, J. Bacteriology, 110: 667-676.

5 The DNA fragment containing the mutant luciferase gene can be obtained from the recombinant DNA using restriction enzymes such as EcoRI and PstI. The reaction mixture is incubated at 30-40°C for 1-24 hours, preferably at 37°C for 2 hours. After digestion, the mixture is electrophoresed on an agarose gel according to the method (Molecular Cloning, 1982, Cold Spring Harbor Laboratory).

10 The nucleotide sequence of a mutant luciferase gene can be determined according to the method as described in Section 17 of Example.

The transformants capable of producing mutant luciferase may be cultured in a solid medium, but a liquid culture medium is preferable.

15 Suitable medium includes more than one nitrogen source among yeast extract, tryptone, peptone, meat extract, corn steep liquor and exudate of soybean or wheat, and more than one inorganic salt among NaCl, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, magnesium sulfate, magnesium chloride, ferric chloride, ferric sulfate, manganese sulfate and the like, and if necessary, some carbohydrates and vitamins.

20 The pH of the culture medium is preferably adjusted to 7-9. Incubation may be carried out at 30-42°C for 4-24 hours, preferably 37°C for 6-8 hours in a submerged aeration culture, a shaking culture, or a stationary culture.

25 After incubation, mutant luciferase is recovered from the culture according to the methods known in the art: Mutant luciferase is recovered by disrupting cells using sonication, mechanical and enzymatic (e.g., lysozyme) lysis or by incubating cells in the presence of toluene with or without shaking and allowing cells to secrete enzyme into the medium. The lysate is filtered or centrifuged to remove cells and cell debris. If it is necessary to remove nucleic acid, streptomycin sulfate, protamine sulfate or manganese sulfate was added to the filtrate or the supernatant. The mixture is then fractionated using ammonium sulfate, alcohol or acetone. The precipitate recovered contains crude luciferase.

30 Crude enzyme thus obtained may be purified by a method or the combination of methods which includes a gel filtration method using Sephadex, Ultro-Gel or Bio-Gel, adsorption chromatography using an ion-exchanger or hydroxyapatite, affinity chromatography, polyacrylamide gel electrophoresis, sucrose density gradient centrifugation, and fractional filtration using a molecular sieve and hollow fiber membrane.

35 Purified luciferase is characterized as follows: Mutant luciferase catalyzes luciferin to produce colors of light, orange (wavelength: 595 nm and 607 nm), red (609 nm and 612 nm) and green (558 nm). The other physical and chemical properties of mutant luciferase of Luciora cruciata are found identical to those of native luciferase as described in the Japanese Patent Appln. LOP Publication No. 141592/1989. Similarly, the other physical and chemical properties of mutant luciferase of Luciora lateralis found identical to those of native luciferase (Japanese Patent Appln. LOP Publication No. 262791/1989).

The Effect of the Invention

40 The present invention provides industrially useful luciferase. Mutant luciferase of the invention is produced by culturing a microorganism belonging to the genus Escherichia which carries the recombinant DNA containing the mutant luciferase gene of a firefly. Mutant luciferase can produce red, orange and green colors of light which are not seen by native luciferase. Mutant luciferase can be used to measure ATP accurately in a colored solution such as red (e.g., blood), orange, or green colors in which native luciferase has not provided reliable results.

Description of the Figures

Fig. 1 shows the restriction map of a recombinant plasmid pALf3.
50 Fig. 2 shows the restriction map of a recombinant plasmid pGLf1.

Example

55 The following example further illustrates the invention.
The following Sections 1-10 describe the construction of a recombinant DNA containing the luciferase cDNA of Photinus pyralis (Photinus pyralis is a member of fireflies). The construct is used as a probe to screen the luciferase gene of Luciora cruciata.

(1) Preparation of a Luciferase mRNA of *Photinus pyralis*

5 1 g of dried tails of *Photinus pyralis* (Sigma) was ground well using a mortar and a pestle. 5 ml of buffer [20 mM Tris-HCl/pH 7.4, 10 mM NaCl, 3 mM magnesium acetate, 5% (w/v) sucrose, 1.2% (v/v) Triton X-100, 10 mM vanadyl nucleoside complex (New England Biolabs)] was added to the material. The material was further ground as described above.

10 5 ml of the solution thus obtained was placed in a blender cup (Nippon Seiki Seisakusho Co.) and mixed at 5,000 r.p.m. for 5 minutes. 12 ml of a guanidine isothiocyanate solution [6 M guanidine isothiocyanate, 37.5 mM sodium citrate/pH 7.0, 0.75% (w/v) sodium N-lauroylsarcosinate, 0.15 M β -mercaptoethanol] was added to the mixture. The mixture was mixed in a blender cup at 3,000 r.p.m. for 10 minutes. Then, the mixture was filtrated through a three-folded gauze. The filtrate was layered onto four ultra-centrifuge tubes (Hitachi Koki Co.) containing 1.2 ml each of 5.7 M cesium chloride. The tube was ultracentrifuged (SCP55H, Hitachi Koki Co.) at 30,000 for 16 hours at 15°C. The precipitate was washed with ice cold 70% (v/v) ethanol and resuspended in 4 ml of 10 mM Tris buffer (10 mM Tris-HCl/pH 7.4, 5 mM EDTA, 1% sodium dodecylsulfate). The mixture was extracted with an equal volume of a n-butanol/chloroform (4:1 v/v) mixture. The extract was centrifuged at 3,000 r.p.m. for 10 minutes. The aqueous phase was saved and 4 ml of 10 mM Tris buffer was added to the organic phase. The organic phase was back-extracted 2x and the aqueous phase was pooled each time. To the combined aqueous phase, 1/10 volume of 3M sodium acetate/pH 5.2 and two volumes of ice cold ethanol were added. The mixture was incubated at -20°C for 2 hours. After incubation, the mixture was centrifuged at 8,000 r.p.m. for 20 minutes. The RNA precipitate was removed and dissolved in 4 ml of water. RNA was precipitated with ethanol and resuspended in 1 ml of water. 3.75 mg of RNA was obtained.

15 The above procedure was repeated and a total amount of RNA recovered was 7 mg. mRNA was separated from total RNA using an oligo (dT) cellulose (New England Biolabs) column chromatography. The oligo (dT) column was prepared by filling a 2.5 ml Terumo syringe column (Terumo Co.) with 0.5 g of resin which had previously been swelled in an elution buffer [10 mM Tris-HCl/pH 7.6, 1 mM EDTA, 0.1% (w/v) sodium dodecylsulfate]. The column was then equilibrated with binding buffer [10 mM Tris-HCl/pH 7.6, 1 mM EDTA, 0.4 M NaCl, 0.1% sodium dodecylsulfate].

20 An equal volume of buffer [10 mM Tris-HCl/pH 7.6, 1 mM EDTA, 0.8 M NaCl, 0.1% sodium dodecylsulfate] was added to the RNA (7 mg) suspension. The mixture was incubated at 65°C for 10 minutes, cooled on ice, and loaded on the oligo (dT) cellulose column. The column was then washed with binding buffer to remove unbound rRNA and tRNA. Elution buffer was loaded on the top of the column to elute mRNA. 40 μ g of mRNA was obtained.

(2) Isolation of Luciferase mRNA

25 mRNA was concentrated using a sucrose density gradient centrifugation. The sucrose gradient was made as follows: 0.5 ml of 40% (w/v) sucrose [50 mM Tris-HCl/pH 7.5, 20 mM NaCl, 1 mM EDTA, 40% (w/v) sucrose] was placed in a polyaroma tube (Beckman rotor SW41). Then, 2.4 ml of each sucrose (25% (w/v), 20% (w/v), 15% (w/v), 10% (w/v)) was layered. The gradient was left standing at 4°C for 24 hours. 30 μ g of mRNA was layered onto the sucrose gradient. The tube was ultracentrifuged at 30,000 r.p.m. at 18°C for 18 hours. After centrifugation, a total volume was removed in a 0.5 ml fraction. Ethanol was added to each fraction. The precipitate was removed and resuspended in 10 μ l of water.

30 The fraction containing a high level of luciferase mRNA was selected as follows: 1 μ l of the fraction, 9 μ l of rabbit reticulocyte lysate (Amersham) and 1 μ l of 35 S-methionine (Amersham) were combined. The mixture was incubated at 30°C for 30 minutes. 150 μ l of NET [150 mM NaCl, 5 mM EDTA, 0.02% (w/v) NaN_3 , 20 mM Tris-HCl/pH 7.4, 0.05% (w/v) Nonidet P-40 (BRL detergent)] was added to the mixture. Then, 1 μ l of anti-luciferase serum (prepared as described in Section 3) was added to the mixture. The mixture was incubated at 4°C for 18 hours. 10 mg of Protein A Sepharose (Pharmacia) was added to the mixture. The mixture was incubated at 20°C for 30 minutes. After incubation, the mixture was centrifuged at 12,000 r.p.m. for one minute. The pellet was recovered and washed 3x with 200 μ l of NET. 40 μ l of sample buffer [62.5 mM Tris-HCl/pH 6.8, 10% (v/v) glycerol, 2% (w/v) sodium dodecylsulfate, 5% (v/v) β -mercaptoethanol, 0.02% (w/v) Bromophenol Blue] was added to the pellet. The mixture was boiled at 100°C for three minutes and centrifuged at 12,000 r.p.m. for one minute. The supernatant was loaded on 12% (w/v) SDS-PAGE. Electrophoresis was carried out according to the method (Laemmli, 1970, Nature p227, p680). After electrophoresis, the gel was immersed in 10% acetic acid for 30 minutes, washed in water for 30 minutes and immersed in 1 M sodium salicylic acid for 30 minutes. The gel was dried and exposed to a X-ray film (Fuji Film Co.) for fluorography.

The film was analyzed: The presence of a band on the film indicated the presence of an elevated level of luciferase mRNA in that fraction.

(3) Preparation of Rabbit Anti-luciferase Serum

Rabbit antiserum against purified luciferase was prepared as follows.

5 0.7 ml of luciferase (3.2 mg/ml) [luciferase (Sigma) was dissolved in 0.5 M glycylglycine/pH 7.8] was mixed with an equal volume of Freund's complete adjuvant (2.24 mg). The mixture was injected to a pad of a Japanese white rabbit (2 kg). The rabbit was boosted two weeks after the first injection with the same amount of the antigen-adjuvant mixture intracutaneously at the back. One week later, the rabbit was boosted as described above. One week after the final injection, the rabbit was sacrificed and bled.

10 The blood was left standing at 4°C for 18 hours and then centrifuged at 3,000 r.p.m. for 15 minutes to give a supernatant containing anti-luciferase serum.

(4) Preparation of a Luciferase cDNA

Luciferase cDNA was prepared using Amersham's kit.

15 cDNA was prepared from 2.0 µg of mRNA according to the method described in Mol. Cell. Biol. 2: 161, 1982 and Gene 25: 263, 1983, as recommended by the manufacturer's instructions.

20 150 ng of cDNA was suspended in 7 µl of TE (10 mM Tris-HCl/pH 7.5, 1 mM EDTA). 11 µl of buffer (280 mM sodium cacodylate/pH 6.8, 60 mM Tris-HCl/pH 6.8, 2 mM cobalt chloride), 3.8 µl of a tailing solution [7.5 µl of 10 mM dithiothreitol, 1 µl of poly A (10 ng/ml), 2 µl of 5 mM dCTP, 110 µl of water] and 29 units of terminal transferase (Boehringer Mannheim Inc.) were added to the suspension. The mixture was incubated at 30°C for 10 minutes. After incubation, 2.4 µl of 0.25 M EDTA and 2.4 µl of 10% (w/v) sodium dodecylsulfate were added to the mixture to stop the reaction.

25 25 µl of phenol equilibrated with water was added to the mixture. The aqueous phase was saved. 25 µl of 4 M ammonium acetate and 100 µl of ice cold ethanol were added to the aqueous portion. The mixture was incubated at -70°C for 15 minutes. After incubation, the mixture was centrifuged at 12,000 r.p.m. for 10 minutes. The pellet was removed and resuspended in 10 µl of TE. The resulting suspension contained 100 ng of deoxycytidine-tailed cDNA.

(5) Preparation of a Vector pMCEI0

30 pKN305 and pMC1403-3 (Japanese Patent Appln. LOP Publication No. 274683/1986) were constructed using *E. coli* W3110 (ATCC 27325), pBR325 (BRL), pBR322 (Takara Shuzo Co., LTD) according to the method described by Masuda, T. et. al., (1986, Agricultural Biological Chemistry 50: 271-279). 1 µg of pKN305 DNA and 1 µg of pMC1403-3 DNA were dissolved in 10 µl of a solution (50 mM Tris-HCl/pH 7.5, 10 mM MgCl₂, 100 mM NaCl, 1 mM dithiothreitol) in a separate tube. 2 units of HindIII and 2 units of Sall (Takara Shuzo Co., LTD) were added to each tube. The mixture was incubated at 37°C for an hour. After digestion, the mixture was extracted with phenol. The extract was then precipitated with ethanol. The precipitate was dissolved in 10 µl of ligation buffer (20 mM MgCl₂, 60 mM Tris-HCl/pH 7.6, 1 mM ATP, 15 mM dithiothreitol). 1 unit of T4 DNA ligase (Takara Shuzo Co., LTD) was added to the solution and the mixture was incubated at 20°C for 4 hours. The mixture was used to transform JMI01 (ATCC 33876) according to the method (J. Bacteriology, 1974, 119: 1072-1074). The transformants were screened on an agar plate containing ampicillin and tetracycline in addition to a necessary culture medium. The transformants were then further screened for the β-galactocidase activity. After screening, a positive colony was found and designated JMI01 (pMCEI0). The recombinant plasmid contained was designated pMCEI0. JMI01 (pMCEI0) was cultured at 37°C for 16-24 hours. 20 ml of the culture was added to 1 l of a culture medium [1% (w/v) tryptone, 0.5% (w/v) yeast extract, 0.5% (w/v) NaCl]. The mixture was incubated at 37°C for three hours. At three hours of incubation, 0.2 g of chloramphenicol was added to the mixture. The mixture was further incubated at 37°C for 20 hours.

The culture was centrifuged at 6,000 r.p.m. for 10 minutes to give 2 g of the cells which were suspended in 20 ml of 350 mM Tris-HCl/pH 8.0 buffer containing 25% (w/v) sucrose. 10 mg of lysozyme, 8 ml of 0.25 M EDTA/pH 8.0 and 8 ml of 20% (w/v) sodium dodecylsulfate were added to the suspension. The mixture was incubated at 60°C for 30 minutes.

55 13 ml of 5 M NaCl was then added to the mixture. The mixture was further incubated at 4°C for 16 hours. After incubation, the mixture was centrifuged at 15,000 r.p.m. for 30 minutes. The supernatant was extracted with phenol. Then, DNA was precipitated with ethanol.

55 The precipitate was dried under reduced pressure and then dissolved in 6 ml of TE. 6 g of cesium chloride and 0.2 ml (10 mg/ml) of ethidium bromide were added to the solution. The mixture was ultracentrifuged at 39,000 r.p.m. for 42 hours. After centrifugation, pMCEI0 DNA portion was removed and extracted with n-butanol to remove ethidium bromide. The DNA solution was then dialyzed against TE. After dialysis, the dialysate con-

tained 500 µg of DNA.

(6) Preparation of Deoxyguanidine-tailed Vector pMCEl0 and pUCI9

5 15 µg of pMCEl0 was dissolved in 90 µl of TE. 10 µl of Med buffer [100 mM Tris-HCl/pH 7.5, 100 mM MgCl₂, 10 mM dithiothreitol, 500 mM NaCl] and 30 units of Accl (Takara Shuzo Co., LTD) were added to the solution. The mixture was incubated at 37°C for an hour. After digestion, the mixture was extracted with 100 µl of phenol equilibrated with water. To the extract, 1/10 volume of 3 M sodium acetate/pH 7.5 and two volumes of ice cold ethanol were added. The mixture was incubated at -70°C for 15 minutes. After incubation, the mixture was centrifuged at 12,000 r.p.m. for 10 minutes. The pellet was resuspended in 10 µl of TE.

10 15 µl of a solution (280 mM sodium cacodylate/pH 6.8, 60 mM Tris-HCl/pH 6.8, 2 mM cobalt chloride), 5 µl of a tailing solution [7.5 µl of 10 mM dithiothreitol, 1 µl of poly A (10 ng/ml), 2 µl of 5 mM dGTP, 110 µl of water] and 5 units of terminal transferase (Takara Shuzo Co., LTD) were added to the mixture. The mixture was incubated at 37°C for 15 minutes. The rest of the procedure was carried out as described in Section 4.

15 The resulting solution contained DNA of pMCEl0 with a deoxyguanosine tail at the Accl site.

DNA of pUCI9 with a deoxyguanosine tail at the PstI site was prepared as follows: 30 µg of pUCI9 (Takara Shuzo Co., LTD) was dissolved in 350 µl of TE. 40 µl of Med buffer and 120 units of PstI (Takara Shuzo Co., LTD) were added to the solution. The mixture was incubated at 37°C for an hour. After digestion, the mixture was extracted with phenol. Then, DNA was precipitated with ethanol.

20 The precipitate was then resuspended in 35 µl of TE. 50 µl of a solution (280 mM sodium cacodylate/pH 6.8, 60 mM Tris-HCl/pH 6.8, 1 mM cobalt chloride), 19 µl of a tailing solution (described above, containing dGTP) and 60 units of terminal transferase (Takara Shuzo Co., LTD) were added to the suspension. The mixture was incubated at 37°C for 10 minutes. After incubation, the mixture was extracted with phenol. DNA was then recovered by ethanol precipitation.

25 (7) Construction of a Luciferase cDNA Library

30 15 ng of deoxycytidine-tailed luciferase cDNA and 200 ng of deoxyguanidine-tailed pMCEl0 were dissolved in 35 µl of annealing buffer (10 mM Tris-HCl/pH 7.5, 100 mM NaCl, 1 mM EDTA) in a tube. Similarly, 15 ng of deoxycytidine-tailed luciferase cDNA and 200 ng of deoxyguanidine-tailed pUCI9 were dissolved in 35 µl of annealing buffer in a tube. The tubes were heated at 65°C for 2 minutes, at 46°C for 2 hours, at 37°C for an hour, and then at 20°C for 18 hours.

35 The constructs (recombinant plasmids of pMCEl0 and pUCI9, which contain luciferase cDNA) were used to transform *E. coli* DHL (ATCC 33849) according to the method described by Hanahan (1985, DNA Cloning, 1: 109-135).

(8) Screening of the Luciferase cDNA Library

40 The Accl site of pMCEl0 was located in the coding region of a β-galactosidase gene. The luciferase cDNA of pMCEl0 produced a fusion protein bound to β-galactosidase. The promoter of the β-galactosidase gene of pMCEl0 had been replaced by that of the tryptophan gene of *E. coli* as described previously.

45 96 colonies of the luciferase cDNA library in the pMCEl0 vector were incubated with shaking in 10 ml of a M9 casamino acid medium (Maniatis, T., 1982, Molecular Cloning, Cold Spring Harbor Laboratory, NY, pp 440-441) containing 10 µg/ml of thiamin at 37°C for 10 hours. After incubation, the bacterial cells were harvested. The cells were suspended in 200 µl of sample buffer (see Section 2). The suspension was boiled at 100°C for 5 minutes.

50 40 µl of the suspension was electrophoresed on a 7.5% (w/v) polyacrylamide gel. After electrophoresis, proteins on the gel were transferred to a nitrocellulose filter according to the western blot analysis (Anal. Biochem. 112: 195, 1981). The nitrocellulose filter was treated with anti-luciferase serum using an immunoblot assay kit (Bio-Rad) according to the method recommended by the manufacturer's instructions: The filter was immersed in 100 ml of a blocking solution [TBS (20 mM Tris-HCl, 500 mM NaCl/pH 7.5) containing 3% (w/v) gelatin] and incubated with shaking at 25°C for 30 minutes. The filter was then transferred to 25 ml of a primary antibody solution [anti-luciferase serum was diluted 1:25 v/v with TBS containing 1% (w/v) gelatin] and incubated with shaking at 25°C for 90 minutes. The filter was transferred to 100 ml of Tween-20 Wash [TBS containing 0.05% (w/v) Tween-20] and incubated with shaking at 25°C for 10 minutes. This washing procedure was repeated one more time. The filter was transferred to 60 ml of a secondary antibody solution [horseradish peroxidase labelled anti-rabbit antibody (Bio-Rad) diluted 1:3000 (v/v) with TBS containing 1% (w/v) gelatin] and incubated with shaking at 25°C for 60 minutes. The filter was washed 2x with 100 ml of Tween-20 Wash.

The filter was then transferred to 120 ml of a staining solution and incubated at 25°C for 10 minutes. The staining solution was prepared as follows: 60 mg of 4-chloro-1-naphthol was dissolved in 20 ml of cold methanol (solution A). 60 µl of 30% (v/v) hydrogen peroxide was added to 100 ml of TBS (solution B). The solution A and B were combined.

- 5 Manipulating 96 colonies as a set, we screened additional three sets of colonies as described above. Two sets were positive. The two sets were further tested: The two sets of colonies were divided into 16 groups (12 colonies per group). The 16 groups were screened as described above. Of these, two groups were positive. 24 colonies were then screened individually as described above. Of these, two positive colonies were found and plasmid DNA of the two colonies was prepared as described in Section 5. The plasmid DNAs were designated pALf2B8 and pALf3A6.
- 10

(9) Preparation of a DNA Probe for the Screening of the Luciferase cDNA Library

15 100 µg of pALf3A6 DNA was dissolved in 330 µl of TE. 40 µl of low buffer (100 mM Tris-HCl/pH 7.5, 100 mM MgCl₂, 10 mM dithiothreitol), 130 units of PstI (Takara Shuzo Co., LTD) and 120 units of SacI (Boehringer Mannheim) were added to the solution. The mixture was incubated at 37°C for 1.5 hours.

20 Digested DNA was electrophoresed on a 0.7% (w/v) agarose gel according to the method described by Maniatis, T., (1984, Molecular Cloning, pp 156-161, Cold Spring Harbor Laboratory, NY). The band containing the luciferase cDNA was cut out and placed in a dialysis tube. 2 ml of TE was added to the tube and the tube was sealed. The tube was subjected to electroelution. The DNA solution was removed from the tube and extracted with an equal volume of phenol equilibrated with water. DNA was precipitated with ethanol.

25 10 µg of DNA thus obtained was resuspended in 126 µl of TE. 16 µl of Med buffer and 64 units of Sau3AI (Takara Shuzo Co., LTD) were added to the suspension. The mixture was incubated at 37°C for 2 hours. After digestion, the restriction fragments were electrophoresed on a 5% (w/v) polyacrylamide gel according to the method described by Maxam, A. (1980, Methods in Enzymology 65: 506). 1 µg of the 190 bp Sau3AI fragment containing the luciferase cDNA was isolated as described above.

30 1 µg of the fragment was labelled with α-³²p-dCTP (Amersham) using a kit (Takara Shuzo Co., LTD) according to the nick translation method (J. Mol. Biol., 1977, 113: 237-251 and Molecular Cloning, 1982, Cold Spring Harbor Laboratory, NY, pp 109-112).

(10) Screening of the Luciferase cDNA Library in the pUC19 Vector Using the ³²p-Labelled Probe

35 The luciferase cDNA library in the pDCI9 vector was screened using the ³²p-labelled probe according to the colony hybridization method (Proteins, Nucleic Acid, Enzyme, 1981, 26: 575-579). Positive colonies were obtained and one of colonies was designated as pALf3. pALf3 DNA was prepared as described in Section 5 and used to transform E. coli DHI. The transformant was designated as DHI (pALf3). DHI (pALf3) was deposited as ATCC 67462.

40 pALf3 DNA was digested with one or two enzymes from the group consisting of XbaI, HindIII, BamHI, EcoRI and PstI (Takara Shuzo Co., LTD). For a molecular weight marker, λDNA (Takara Shuzo Co., LTD) was digested with HindIII. The restriction fragments were electrophoresed on an agarose gel. The band patterns of digested pALf3 DNA were compared with those of the λDNA marker. The size of the luciferase cDNA fragment was found to be 1,700 bp. The restriction map of pALf3 is shown in Fig. 1.

(11) Preparation of Luciferase mRNA of Luciola cruciata

45 10 g of living Luciola cruciata (purchased from Seibu Department Store) was placed in an ultracold freezer. After the insect was frozen they were taken out from the freezer. The tails of fireflies were cut off with scissors to yield 2 g of the tails. 18 ml of a guanidine isothiocyanate solution was added to 2 g of the tails. 1.1 mg of total RNA was recovered and loaded onto the top of an oligo (dT) cellulose column according to the method as described in Section 1. 30 µg of luciferase mRNA was recovered.

(12) Construction of the Luciferase cDNA Library of Luciola cruciata

50 cDNA was prepared using a kit (Amersham) according to the method (Mol. Cell. Biol., 1982, 2: 161 and Gene, 1983, 25: 263).

0.9 µg of double-stranded cDNA was prepared from 2 µg of mRNA. 0.3 µg of cDNA was polydeoxycytidine-tailed according to the method as described in Section 4.

20 ng of polydeoxycytidine-tailed cDNA and 500 ng of polydeoxyguanocine-tailed pUC19 DNA (see Section

6) were annealed according to the method as described in Section 7. The construct was used to transform E. coli DHI (ATCC 33849) according to the method described by Hanahan (1985, DNA Cloning, 1: 109-135).

(13) Screening of the Luciferase cDNA Library

5 10 µg of pALf3 DNA as described in Section 10 was dissolved in 90 µl of TE. 10 µl of Med buffer, 25 units each of EcoRI and Clal (Takara Shuzo Co., LTD) were added to the solution. The mixture was incubated at 37°C for 2 hours. After digestion, the restriction fragments were electrophoresed on an agarose gel. The 800 bp EcoRI-Clal fragment containing luciferase cDNA was isolated. 1 µg of the DNA fragment recovered was labelled with α -³²p-dCTP (Amersham) according to the nick translation method. The luciferase cDNA library of Luciola cruciata was screened using the ³²p-labelled probe according to the colony hybridization method. Several positive colonies were obtained and one of the colonies was designated at pGLf1. pGLf1 DNA was prepared according to the method as described in Section 5, and used to transform E. coli DHI. The transformant was designated as DHI (pGLf1). DHI (pGLf1) was deposited as ATCC 67482.

10 pGLf1 DNA was digested with one or two enzymes from the group consisting of HpaI, HindIII, EcoRV, DraI, AflII, HinclI, PstI (Takara Shuzo Co., LTD) and SspI (New England Bio-Laboratory). For a molecular weight marker, λ phage DNA (Takara Shuzo Co., LTD) was digested with HindIII. The restriction fragments were electrophoresed on an agarose gel. The band patterns were analyzed. The fragment containing luciferase cDNA was 2,000 bp. The restriction map of pGLf1 is shown in Fig. 2.

20 (14) DNA Sequencing of the Luciferase cDNA of Luciola cruciata

25 10 µg of pGLf1 DNA was digested with PstI (Takara Shuzo Co., LTD). After digestion, 2.5 µg of the 2.0 kb DNA fragment containing the luciferase cDNA was recovered. The 2.0 kb fragment was inserted into the PstI site of pUC19 (Takara Shuzo Co., LTD). The constructs were designated as pGLf2 and pGLf3 according to the orientation of the inserted fragment.

The recombinant plasmids pGLf2 and pGLf3 were constructed as follows:

30 pGLf1 DNA and pUV19 DNA were digested with PstI according to the method as described in Section 6. The luciferase cDNA fragment was isolated by agarose gel electrophoresis according to the method as described in Section 9. The restriction fragments of the vector and the insert were ligated according to the method as described in Section 5. JMI01 (ATCC 33876) was transformed with the constructs according to the method as described in Section 5. DNA of pGLf2 and pGLf3 was prepared according to the method as in Section 5.

35 Various deletion mutations were introduced into pGLf2 and pGLf3 using a kilosequence deletion kit (Takara Shuzo Co., LTD) according to the method described by Henikoff (1984, Gene 28: 351-359). E. coli JMI01 (ATCC 33876) was then transformed with the deletion mutants of pGLf2 and pGLf3. The transformants were infected with a helper phage M13K07 (Takara Shuzo Co., LTD) to prepare single-stranded DNA according to the method described by Messing (1983, Methods in Enzymology, 101: 20-78). Single-stranded DNA was sequenced using a M13 sequencing kit (Takara Shuzo Co., LTD) according to the method (Messing, see above). Sequencing was carried out on a polyacrylamide gel (Fuji Film Co., LTD).

40 The nucleotide sequence of the luciferase cDNA of Luciola cruciata is shown in the Sequence Listing SEQ ID: No. 1. The amino acid sequence deduced from the nucleotide sequence is shown in the Sequence Listing SEQ ID: No. 2.

(15) Construction of a Recombinant Plasmid pGLf37

45 The 4.0 kb DNA fragment containing most of the vector segment as well as the luciferase cDNA lacking 27 nucleotides at the N-terminal was prepared as follows:

50 1 µg of pGLf1 DNA was dissolved in 90 µl of water. 10 µl of Med buffer and 20 units of PstI (Takara Shuzo Co., LTD) were added to the solution. The mixture was incubated at 37°C for 2 hours. After digestion, an equal volume of phenol equilibrated with water was added to the mixture. The DNA fragments were recovered by ethanol precipitation, and inserted into a vector. The constructs were used to transform E. coli JMI01 (ATCC 33876), and plasmid DNA was prepared from the transformants according to the method as in Section 5.

55 Plasmid DNA of the transformants was digested with one or two enzymes from the group consisting of SspI, EcoRV and PstI. The construct containing the cDNA fragment in the orientation opposite to the one in pGLf1 was designated as pGLf10.

10 10 µg of pGLf10 DNA was dissolved in 90 µl of water. 10 µl of Med buffer and 10 units of SspI (New England Bio-Lab) were added to the solution. The mixture was incubated at 37°C for 30 minutes. After partial digestion, the 4.0 kb DNA fragment (2 µg) containing most of the vector segment as well as the luciferase cDNA lacking

27 nucleotides at the N-terminal was recovered.

1 µg of the 4.0 kb DNA fragment was dissolved in 95 µl of water. 5 µl of 1 M Tris-HCl/pH 8.0 and 1 µl (0.3 unit) of alkaline phosphatase (Takara Shuzo Co., LTD) were added to the solution. The mixture was incubated at 65°C for an hour. After dephosphorylation, the mixture was extracted with phenol. Then, DNA was precipitated with ethanol. 1 µg of the 4.0 kb DNA fragment dephosphorylated at both ends was recovered.

5 The DNA fragment containing the trp promoter of *E. coli* was prepared as follows:

10 10 µg of pKN206 DNA containing a trp promoter (Agric. Biol. Chem. 1986, 50: 271-279) was dissolved in 90 µl of water. 10 µl of Med buffer and 20 units of Cial (Takara Shuzo Co., LTD) were added to the solution and the mixture was incubated at 37°C for 2 hours. After complete digestion, the restriction fragments were further digested with 10 units of Sspl at 37°C for 30 minutes. After partial digestion with Sspl, the DNA fragments were extracted with phenol. Then, DNA was precipitated with ethanol. The precipitate was resuspended in 100 µl of TE. The 500 bp DNA fragment containing almost all the trp promoter was isolated according to the method described in Section 9.

15 Oligonucleotides for the 4.0 kb fragment and the trp promoter were synthesized as follows:

10 The luciferase cDNA of the 4.0 kb DNA fragment lacked the nucleotide sequence encoding nine amino acids at N-terminal according to the nucleotide sequence analysis. The trp promoter of the 500 bp DNA fragment lacked part of the sequence between the SD region and the ATG initiation codon. To fill the missing sequences of the 4.0 kb DNA fragment and the trp promoter, two oligonucleotides as defined in the Sequence Listing by SEQ: ID Nos. 3 and 4 were synthesized using a System 1 Plus DNA synthesizer (Beckman).

20 The oligomers were purified using a NENSORB PREP (Dupont) and 20 µg of each oligomer was recovered. 1 µg each of the purified oligomers was dissolved in 45 µl of water in a separate tube. 5 µl of 10x kination buffer (0.5 M Tris-HCl/pH 7.6, 0.1 M MgCl₂, 50 mM dithiothreitol, 10 mM ATP) and 1 µl (10 unit) of T4 polynucleotide kinase (Takara Shuzo Co., LTD) were added to the tubes. The mixtures were incubated at 37°C for an hour. The mixtures were extracted with phenol. Then, DNA was precipitated with ethanol. 1 µg each of the oligomer phosphorylated at the 5' end was recovered.

25 A recombinant plasmid pGLf37 was constructed as follows:

30 1 µg of the 4.0 kb fragment, 1 µg of the 500 bp fragment and 0.1 µg each of the oligomer phosphorylated as above were dissolved in 8 µl of water. 1 µl of 10x ligation buffer (200 mM MgCl₂, 660 mM Tris-HCl/pH 7.6, 10 mM ATP, 150 mM dithiothreitol) and 1 µl (1 unit) of T4 DNA ligase (Takara Shuzo Co., LTD) were added to the mixture. The mixture was incubated at 16°C for 16 hours. Then, the mixture was used for transformation. Transformation of JM101 (ATCC 33876) and isolation of plasmid DNA were carried out in an analogous way as in Section 5. Plasmid DNA was digested with one or two enzymes from the group consisting of Sspl, EcoRV and PstI. The restriction fragments were electrophoresed on a 0.7% agarose gel. The recombinant plasmid containing the trp promoter and the luciferase cDNA was selected and designated as pGLf37. A JM101 transformant carrying pGLf37 was designated as JM101 (pGLf37).

(16) Mutagenesis of Recombinant Plasmid pGLf37

35 30 µg of pGLf37 DNA was dissolved in 100 µl of a hydroxylamine solution (0.8 M hydroxylamine hydrochloride, 0.1 M phosphate buffer/pH 6.8, 1 mM EDTA). The mixture was incubated at 65°C for 2 hours. After incubation, DNA was precipitated with ethanol in conventional way. The precipitate was resuspended in TE (10 mM Tris-HCl/pH 7.5, 1 mM EDTA). The mixture was used to transform *E. coli* JM101 (ATCC 33876) according to the method described by Hanahan (1985, DNA Cloning, 1: 109-135). The mixture containing the transformants was plated out on an LB-amp agar plate [1% (w/v) bactotrypton, 0.5% (w/v) yeast extract, 0.5% (w/v) NaCl, 50 µg/ml of ampicillin, 1.4% (w/v) agar]. The plate was incubated at 37°C for 12 hours. A colony appeared on the plate was inoculated into 3 ml of an LB-amp medium [1% (w/v) bactotrypton, 0.5% (w/v) yeast extract, 0.5% (w/v) NaCl, 50 µg/ml of ampicillin] and incubated with shaking at 37°C for 18 hours. 0.5 ml of the culture was added to 10 ml of an LB-amp medium. The mixture was incubated with shaking at 37°C for 4 hours. After incubation, the mixture was centrifuged at 8,000 r.p.m. for 10 minutes.

40 20 mg of the cells collected was suspended in 0.9 ml of a buffer (0.1 M KH₂PO₄/pH 7.8, 2 mM EDTA, 1 mM dithiothreitol, 0.2 mg/ml of protamine sulfate). 100 µl of lysozyme solution (10 mg/ml) was added to the suspension. The mixture was placed on ice for 15 minutes. The mixture was then frozen in a dry ice/methanol bath. The mixture was removed from the bath and left standing at 25°C. When the mixture was completely thawed, it was centrifuged at 12,000 r.p.m. for 5 minutes. 1 ml of a supernatant containing crude enzyme was obtained.

45 50 µl of the crude enzyme solution thus obtained was added to 400 µl of a luciferin/ATP mixture [260 µl of 25 mM glycylglycine/pH 7.8, 16 µl of 0.1 M magnesium sulfate, 24 µl of 1 mM luciferin (Sigma), 100 µl of 10 mM ATP] to observe the color of the light. There were six types of colors: red (609 nm and 612 nm), orange

(595, 607), green (two 558's).

Alternatively, crude enzyme was purified according to the method described in the Japanese Patent Appln. LOP Publication No. 141592/1989, tested, and found the same color displayed as described above.

Recombinant DNAs encoding mutant luciferase which produces red colors of light (609 nm and 612 nm) were designated as pGLf37C-M-2 and pGLf37C-M-5, respectively. *E. coli* JMI01 was transformed with pGLf37C-M-2 or pGLf37C-M-5. The transformants, *E. coli* JMI01 (pGLf37C-M-2) and JMI01 (pGLf37C-M-5) were deposited with Fermentation Research Institute, Agency of Industrial Science and Technology and were assigned the accession number FERM BP-2825 and FERM BP-3136, respectively. Recombinant DNAs encoding mutant luciferase which produces orange colors of light (595 nm and 607 nm) were designated as pGLf37C-M-4 and pGLf37C-M-1, respectively. The transformants, *E. coli* JMI01 (pGLf37C-M-4) and JMI01 (pGLf37C-M-1), were deposited with the same and were assigned the accession number FERM BP-2826 and FERM BP-3135, respectively. Recombinant DNAs encoding mutant luciferase which produces green colors of light (two wavelengths of 558 nm) were designated as pGLf37C-M-6 and pGLf37C-M-7, respectively. The transformants, *E. coli* JMI01 (pGLf37C-M-6) or JMI01 (pGLf37C-M-7), were deposited with the same and were assigned the accession number FERM BP-3137 and FERM BP-3138, respectively.

Table I summarizes the color of light, the position of mutation in the nucleotide sequence and the position of mutation in the amino acid sequence of the bacterial strains.

20

25

30

35

40

45

50

55

5

10

15

20

25

30

35

40

45

50

55

Table I

Bacterial Strains	Color of Light (wavelength)	Base Substitution & its Position	Amino Acid Substitution & its Position
<u>E. coli</u> JM101 (pGUF37C-M-2)	Red (609 nm)	G → A 976	Gly → Ser 326
<u>E. coli</u> JM101 (pGUF37C-M-5)	Red (612 nm)	C → T 1297	His → Tyr 433
<u>E. coli</u> JM101 (pGUF37C-M-4)	Orange (595 nm)	C → T 1354	Pro → Ser 452
<u>E. coli</u> JM101 (pGUF37C-M-1)	Orange (607 nm)	G → A 857	Ser → Asn 286
<u>E. coli</u> JM101 (pGUF37C-M-6)	Green (558 nm)	G → A 715	Val → Ile 239
<u>E. coli</u> JM101 (pGUF37C-M-7)	Green (558 nm)	G → A 697	Val → Ile 233

SEQUENCE LISTING

5 (2) INFORMATION FOR SEQ ID NO: 1

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1644 Base pairs

10 (B) TYPE: Nucleic acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

15 (ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE

(A) ORGANISM: Luciola cruciata

20 (ix) FEATURES

(A) OTHER INFORMATION

Luciferase cDNA

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1

	10	20	30	40	50	60
	ATGGAAAAC	TGGAAAACGA	TGAAAATATT	GTA	TTACCC	TATC
30	70	80	90	100	110	120
	GAAGAGGG	AT	CTGCTGGAAC	ACAATTACGC	AAATACATGG	ACCGATATGC
	130	140	150	160	170	180
	GCAATTG	C	TTACAAATGC	AGTTACTGGT	GTTGATTATT	CTTACGCCGA
	190	200	210	220	230	240
	AAATCATG	T	TGCTAGGAA	AGCTTTGCAA	AATTATGGTT	TGGCAGAATT
35	250	260	270	280	290	300
	GCGTTATG	C	GTGAAAAC	TG	TAA	TAGCCGG
	310	320	330	340	350	360
	GGTGTAGGT	G	TTGCACCCAC	TAATGAGATT	TACACTTAC	GTGAACTGGT
	370	380	390	400	410	420
	GGTATCTCT	A	ACCAACAAT	TGTATTAGT	TCTAAAAAAG	GCTTAGATAA
40	430	440	450	460	470	480
	GTACAGAAA	CAGTA	ACTAC	TAT	TA	TAGCAAA
	490	500	510	520	530	540
	CGAGGATATC	AAT	GTC	TGGA	CAC	CTCCACCA
	550	560	570	580	590	600
	TCCAGTTCA	AAAC	TGTGG	AGTTGACCGT	AAAGAACAA	TTGCTCTTAT
45	610	620	630	640	650	660
	TCGGGTTCTA	CCGGTTTG	GC	AAAAGGCC	TA	AGTC
	670	680	690	700	710	720
	TTTTCTCATG	CTA	GAGATCC	GAT	TATGGT	AACCAAGTT
	730	740	750	760	770	780
	ACTGTCGTTC	CATTCC	CATCA	TGG	TTGGT	ATGTTCA
50	790	800	810	820	830	840
	GGTTTTCGTG	TTG	TAATGTT	AA	CATTTTAA	AACTCTACAA

850 860 870 880 890 900
 GATTATAAAAT GTACAAGTGT TATTCTTGTA CCGACCTTGT TTGCAATTCT CAACAAAAGT
 910 920 930 940 950 960
 GAATTACTCA ATAAATACGA TTGTCAAAT TTAGTTGAGA TTGCATCTGG CGGAGCACCT
 970 980 990 1000 1010 1020
 TTATCAAAAG AAGTTGGTGA AGCTGTTGCT AGACGCTTTA ATCTTCCCGG TGTCGTCAA
 1030 1040 1050 1060 1070 1080
 GGTTATGGTT TAACAGAAAC AACATCTGCC ATTATTATTA CACCAAGG AGACGATAAA
 1090 1100 1110 1120 1130 1140
 CCAGGAGCTT CTGGAAAAAGT CGTGCCGTTG TTTAAAGCAA AAGTTATTGA TCTTGATACC
 1150 1160 1170 1180 1190 1200
 AAAAAATCTT TAGGTCTAA CAGACGTGGA GAAGTTTGTG TTAAAGGACC TATGCTTATG
 1210 1220 1230 1240 1250 1260
 AAAGGTTATG TAAATAATCC AGAACGAAACA AAAGAACCTTA TTGACGAAGA AGGTTGGCTG
 1270 1280 1290 1300 1310 1320
 CACACCGGAG ATATTGGATA TTATGATGAA GAAAAACATT TCTTTATTGT CGATCGTTG
 1330 1340 1350 1360 1370 1380
 AAGTCTTAA TCAAATACAA AGGATACCAA GTACCACCTG CCGAATTAGA ATCCGTTCTT
 1390 1400 1410 1420 1430 1440
 TTGCAACATC CATCTATCTT TGATGCTGGT GTGCCGGCG TTCCTGATCC TGTAGCTGGC
 1450 1460 1470 1480 1490 1500
 GAGCTTCCAG GAGCCGTTGT TGTACTGGAA AGCGGAAAAAA ATATGACCGA AAAAGAAGTA
 1510 1520 1530 1540 1550 1560
 ATGGATTATG TTGCAAGTCA AGTTCAAAAT GCAAAACGTT TACGTGGTGG TGTCGTTTT
 1570 1580 1590 1600 1610 1620
 GTGGATGAAAG TACCTAAAGG TCTTACTGGG AAAATTGACG GCAGAGCAAT TAGAGAAATC
 1630 1640
 CTTAAGAAAC CAGTTGCTAA GATG

(3) INFORMATION FOR SEQ ID NO: 2

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 548 Amino acids

(B) TYPE: Amino acid

(C) STRANDEDNESS: -

(D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: Peptide

(vi) ORIGINAL SOURCE

(A) ORGANISM: *Luciola cruciata*

(ix) FEATURES

(A) OTHER INFORMATION

Luciferase

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2

Met Glu Asn Met Glu Asn Asp Glu Asn Ile Val Val Gly Pro Lys Pro Phe Tyr Pro Ile
 10 Glu Glu Gly Ser Ala Gly Thr Gln Leu Arg Lys Tyr Met Glu Arg Tyr Ala Lys Leu Gly
 20 30
 5 Ala Ile Ala Phe Thr Asn Ala Val Thr Gly Val Asp Tyr Ser Tyr Ala Glu Tyr Leu Glu
 40 50
 Lys Ser Cys Cys Leu Gly Lys Ala Leu Gln Asn Tyr Gly Leu Val Val Asp Gly Arg Ile
 60 70
 Ala Leu Cys Ser Glu Asn Cys Glu Glu Phe Phe Ile Pro Val Ile Ala Gly Leu Phe Ile
 80 90
 10 110
 Gly Val Gly Val Ala Pro Thr Asn Glu Ile Tyr Thr Leu Arg Glu Leu Val His Ser Leu
 120 130
 Gly Ile Ser Lys Pro Thr Ile Val Phe Ser Ser Lys Lys Gly Leu Asp Lys Val Ile Thr
 140 150
 Val Gln Lys Thr Val Thr Ile Lys Thr Ile Val Ile Leu Asp Ser Lys Val Asp Tyr
 160 170
 Arg Gly Tyr Gln Cys Leu Asp Thr Phe Ile Lys Arg Asn Thr Pro Pro Gly Phe Gln Ala
 180 190
 Ser Ser Phe Lys Thr Val Glu Val Asp Arg Lys Glu Gln Val Ala Leu Ile Met Asn Ser
 200 210
 Ser Gly Ser Thr Gly Leu Pro Lys Gly Val Gln Leu Thr His Glu Asn Thr Val Thr Arg
 220 230
 20 Phe Ser His Ala Arg Asp Pro Ile Tyr Gly Asn Gln Val Ser Pro Gly Thr Ala Val Leu
 240 250
 Thr Val Val Pro Phe His His Gly Phe Gly Met Phe Thr Thr Leu Gly Tyr Leu Ile Cys
 260 270
 Gly Phe Arg Val Val Met Leu Thr Lys Phe Asp Glu Glu Thr Phe Leu Lys Thr Leu Gln
 280 290
 25 Asp Tyr Lys Cys Thr Ser Val Ile Leu Val Pro Thr Leu Phe Ala Ile Leu Asn Lys Ser
 300 310
 Glu Leu Leu Asn Lys Tyr Asp Leu Ser Asn Leu Val Glu Ile Ala Ser Gly Gly Ala Pro
 320 330
 Leu Ser Lys Glu Val Gly Glu Ala Val Ala Arg Phe Asn Leu Pro Gly Val Arg Gln
 340 350
 30 Gly Tyr Gly Leu Thr Glu Thr Thr Ser Ala Ile Ile Ile Thr Pro Glu Gly Asp Asp Lys
 360 370
 Pro Gly Ala Ser Gly Lys Val Val Pro Leu Phe Lys Ala Lys Val Ile Asp Leu Asp Thr
 380 390
 Lys Lys Ser Leu Gly Pro Asn Arg Arg Gly Glu Val Cys Val Lys Gly Pro Met Leu Met
 400 410
 35 Lys Gly Tyr Val Asn Asn Pro Glu Ala Thr Lys Glu Leu Ile Asp Glu Glu Gly Trp Leu
 420 430
 His Thr Gly Asp Ile Gly Tyr Tyr Asp Glu Glu Lys His Phe Phe Ile Val Asp Arg Leu
 440 450
 Lys Ser Leu Ile Lys Tyr Lys Gly Tyr Gin Val Pro Pro Ala Glu Leu Glu Ser Val Leu
 460 470
 40 Leu Gln His Pro Ser Ile Phe Asp Ala Gly Val Ala Gly Val Pro Asp Pro Val Ala Gly
 480 490
 Glu Leu Pro Gly Ala Val Val Leu Glu Ser Gly Lys Asn Met Thr Glu Lys Glu Val
 500 510
 Met Asp Tyr Val Ala Ser Gln Val Ser Asn Ala Lys Arg Leu Arg Gly Gly Val Arg Phe
 520 530
 45 Val Asp Glu Val Pro Lys Gly Leu Thr Gly Lys Ile Asp Gly Arg Ala Ile Arg Glu Ile
 540
 Leu Lys Lys Pro Val Ala Lys Met

5 (4) INFORMATION FOR SEQ ID NO:3

10 (i) SEQUENCE CHARACTERISTICS:

15 (A) LENGTH: 32 base pairs

(B) TYPE: Nucleic acid

(C) STRANNESS: Single

(D) TOPOLOGY: Linear

20 (ii) MOLECULE TYPE: Other nucleic acid
Oligomer

25 (ix) FEATURES

30 (A) OTHER INFORMATION
A part of SD-ATG DNA fragment of trp promoter +27
nucleotides of N-terminal of wild type luciferase

35 (xi) SEQUENCE DESCRIPTION: SEQ ID:NO 3

CGACAATGGAAAACATGGAAAACGATGAAAAT

40 (5) INFORMATION FOR SEQ ID NO:4

45 (i) SEQUENCE CHARACTERISTICS:

50 (A) LENGTH: 30 bases

(B) TYPE: Nucleic acid

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

55 (ii) MOLECULE TYPE: Other nucleic acid
Oligomer

60 (ix) FEATURES

65 (A) OTHER INFORMATION
A part of SD-ATG DNA fragment of trp promoter +27
nucleotides of N-terminal of wild type luciferase

70 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4

ATTTCATCGTTTCCATGTTTCCATTGT

Claims

- 5 1. A mutant luciferase which has the amino acid sequence of wild type luciferase with at least one of the mutations wherein valine is replaced by isoleucine at the amino acid number 233, valine by isoleucine at 239, serine by asparagine at 286, glycine by serine at 326, histidine by tyrosine at 433 or proline by serine at 452 in the sequence.
- 10 2. A mutant luciferase gene encoding the amino acid sequence of a mutant luciferase as claimed in claim 1.
3. A recombinant DNA comprising a mutant luciferase gene as claimed in claim 2.
- 15 4. A method of producing a mutant luciferase which comprises culturing in a medium a microorganism belonging to the genus Escherichia transformed with a recombinant DNA containing a mutant gene encoding the amino acid sequence of wild type luciferase with at least one of the mutations wherein valine is replaced by isoleucine at the amino acid number 233, valine by isoleucine at 239, serine by asparagine at 286, glycine by serine at 326, histidine by tyrosine at 433 or proline by serine at 452 in the amino acid sequence and recovering mutant luciferase from the culture.
- 20 5. A method of producing a mutant luciferase gene by treating a wild type luciferase gene of a firefly with a mutagen.
- 25 6. A method according to claim 5 wherein the mutant luciferase gene obtained encodes mutant luciferase which catalyses luciferin to produce light of a different wavelength from that produced by native luciferase.
7. A method according to claim 6 wherein the mutant luciferase catalyses luciferin to produce red, orange or green light.
- 30 8. Use of a mutant luciferase as claimed in claim 1 for measuring the amount of ATP in a coloured solution.
9. An ATP assay kit comprising a mutant luciferase as claimed in claim 1 and luciferin.
- 35 10. A microorganism belonging to the genus Escherichia transformed with a recombinant DNA as claimed in claim 3 and selected from FERM BP-2825, FERM BP-2826, FERM BP-3135, FERM BP-3136, FERM BP-3137 and FERM BP-3138.

40

45

50

55

FIG. 1





FIG. 2





European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 91 30 2717

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
Y	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 82, no. 23, December 1985, WASHINGTON US pages 7870 - 7873; J.R. de Wet et al.: "Cloning of firefly luciferase cDNA and the expression of active luciferase in E.coli" * page 3870, left-hand column, lines 19 - 30 + * page 3873, left-hand column, line 24 - right-hand column, line 6 *	1, 2, 4, 8-10	C12N15/53 C12N9/02 C12Q1/66 C12P21/02
Y	SCIENCE. vol. 244, no. 4905, 12 May 1989, LANCASTER, PA US pages 700 - 702; K.V.Wood et al.: "Complementary DNA coding click beetle luciferases can elicit bioluminescence of different colors" * the whole document *	1, 2, 4, 8-10	
A	EP-A-4913 (HENKEL KGAA) * page 17, line 25 - page 18, line 31 *	5	
A	EP-A-301541 (KIKKOMAN CORPORATION)	1-10	TECHNICAL FIELDS SEARCHED (Int. Cl.5)
D	* abstract * & JP-A-1051086		C12N15 C12N9 C12Q1
The present search report has been drawn up for all claims			
Place of search BERLIN	Date of completion of the search 05 JUNE 1991	Examiner GURDJIAN D.	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application I : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			